Polymyositis News

Nearly 1 year ago, I wrote my first editorial about the emergence and excitement surrounding the early experience with CAR T cells — CAR T Cells in Autoimmunity: A Potential Therapy About to Explode.

ORLANDO, Fla. — Malignancies and lung involvement are the two key manifestations of dermatomyositis that require vigilance, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

Rheumatoid arthritis and fibromyalgia are among the most common comorbidities identified in patients following a diagnosis of osteoarthritis, according to data presented at the EULAR 2024 Congress.

DESTIN, Fla. — Positive results for chimeric antigen receptor T-cell therapy in systemic sclerosis and myositis have added fuel to the fire of recent landmark data in lupus, said a speaker at the Congress of Clinical Rheumatology East.

DESTIN, Fla. — Although the strongest predictor of malignancy in dermatomyositis is age, all adult patients should undergo cancer screening, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

Single injections of CD19 chimeric antigen receptor T-cell therapy brought long-lasting remission to 15 patients with three different autoimmune diseases, according to data published in The New England Journal of Medicine.

Chimeric antigen receptor T-cell therapy produced persistent, drug-free remission in patients with one of three different B-cell autoimmune diseases, researchers reported at ASH Annual Meeting and Exhibition.

SAN DIEGO — Pregnant patients with concomitant systemic lupus erythematosus and antiphospholipid syndrome have an 18-fold increased risk for cardiovascular events vs. healthy pregnant controls, said a speaker at ACR Convergence 2023.

The FDA has granted 510(k) clearance to Werfen for its Aptiva Connective Tissue Disease Essential reagent to assist in the diagnosis of patients with autoimmune diseases, according to a manufacturer press release.